Abstracts tagged "WOMAC"

Abstract Number: 0724 • ACR Convergence 2021
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
Martin Boucher¹, Kenneth Verburg², Puneet Gaitonde² and Scott marshall¹, ¹Pfizer R&D Ltd., Sandwich, United Kingdom, ²Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized monoclonal antibody against nerve growth factor that has been evaluated for relief of chronic osteoarthritis pain by subcutaneous (SC) or…
Abstract Number: 0731 • ACR Convergence 2021
An Open-Label Study to Evaluate the Effect of Intra-articular Triamcinolone Acetonide Extended Release on Patients with Baseline Synovitis and Osteoarthritis of the Knee
Kim Huffman¹, Alan Kivitz², Philip Conaghan³, Michael Bowes⁴, Alan Brett⁴, Virginia Kraus¹, William Maloney⁵, Javad Parvizi⁶, Amy Cinar⁷, Neil Bodick⁷ and Scott Kelley⁷, ¹Duke University School of Medicine, Durham, NC, ²Altoona Center for Clinical Research, Duncansville, PA, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Imorphics Ltd, Manchester, United Kingdom, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Thomas Jefferson University Hospital, Philadelphia, PA, ⁷Flexion Therapeutics Inc., Burlington, MA
Background/Purpose: Synovial inflammation is common in knee osteoarthritis (OA) and is associated with pain and disease severity. Previous studies have suggested short-term (approximately 2 weeks)…
Abstract Number: 1130 • ACR Convergence 2021
Osteoarthritis Patients Feel Their Tissue Remodeling
Anne-Christine Bay-Jensen¹, Yi He², Christian Thudium¹ and Morten Karsdal³, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience A/S, Herlev, Denmark, ³Nordic Bioscience, Herlev
Background/Purpose: Osteoarthritis (OA) is a chronic disease characterized by pain and disability. Central to the revised FDA guidelines for the approval of a disease modifying…
Abstract Number: 1486 • ACR Convergence 2020
Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study
Felix Eckstein¹, Marc Hochberg², Hans Guehring³, Flavie Moreau⁴, Victor Ona⁴, Asger Bihlet⁵, Inger Byrjalsen⁵, Jeppe Andersen⁵, Benjamin Daelken³, Oliver Guenther³, Christoph Ladel³, Martin Michaelis³ and Philip G Conaghan⁶, ¹Paracelsus Medical University, Salzburg, Austria, ²University of Maryland School of Medicine, Baltimore, MD, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵Nordic Bioscience, Herlev, Denmark, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: The 5-year Phase II FORWARD study assessed the efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin (recombinant human fibroblast growth factor…
Abstract Number: 1640 • ACR Convergence 2020
Clinically Important Improvement in Osteoarthritis Pain at Week 16 After Subcutaneous Administration of Tanezumab: Pooled Analysis from International Studies
Thomas Schnitzer¹, Francis Berenbaum², Philip G Conaghan³, Robert Dworkin⁴, Takaharu Yamabe⁵, Isabelle Davignon⁵, Stefan Wilhelm⁶, Erika Dragon⁷ and Lars Viktrup⁶, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁴University of Rochester School of Medicine and Dentistry, Rochester, NY, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Ltd, Budapest, Hungary
Background/Purpose: Tanezumab is under investigation for the treatment of moderate to severe OA pain. As part of the phase 3 OA program, two randomized, placebo-controlled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].